Annual report
4886.TEDINET S100R645
Period2022-04-01 → 2023-03-31
Filed2023-06-27
StandardJapan GAAP
ConsolidatedYes
Data checks22 of 22 passed
Key figures · 72
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥60.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥56.6bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Operating income | ¥5.1bn | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Operating income | ¥4.8bn | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | ¥5.2bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥4.9bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Profit before tax | ¥5.4bn | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥6.2bn | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥4.2bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥4.3bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥4.2bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Net income | ¥4.3bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥87.1bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥83.3bn | at 2022-03-31 | Cons. | Assets |
| Total liabilities | ¥32.6bn | at 2023-03-31 | Cons. | Liabilities |
| Total liabilities | ¥34.4bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥54.5bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥48.9bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥44.5bn | at 2021-03-31d | Cons. | Net assets |
| Cash and deposits | ¥14.5bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥12.1bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥17.5bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥17.1bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.5bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥3.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.8bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥1.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥6.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥1.8bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥3.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥150.08 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥151.22 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥1,928.14 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,734.8 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 62.6% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 58.7% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 8.2% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.8% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| Employees | 747 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 777 | at 2022-03-31 | Cons. | Number of employees |
| Revenue | ¥1.7bn | 2022-04-01 → 2023-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥1.4bn | 2021-04-01 → 2022-03-31 | Standalone | Operating revenue1 |
| Operating income | ¥658m | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Operating income | ¥717m | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | ¥603m | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥717m | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Profit before tax | ¥603m | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥717m | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | ¥591m | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥682m | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Total assets | ¥41.6bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥41.3bn | at 2022-03-31 | Standalone | Assets |
| Total liabilities | ¥630m | at 2023-03-31 | Standalone | Liabilities |
| Total liabilities | ¥606m | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥40.9bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥40.7bn | at 2022-03-31 | Standalone | Net assets |
| Cash and deposits | ¥1.1bn | at 2023-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥820m | at 2022-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥20.95 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥23.79 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥16 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥15 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,447.55 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,443.94 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 98.5% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 98.5% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 1.5% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 1.7% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 30,563,199 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 30,563,199 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Employees | 79 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 74 | at 2022-03-31 | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 55
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2023-03-31 | 14 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2023-03-31 | ¥298m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2023-03-31 | ¥220m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥77m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2023-03-31 | ¥42m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2023-03-31 | −¥6m |
| Reconciling Itemsreconciling | depreciation | 2022-04-01 → 2023-03-31 | ¥481m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2023-03-31 | −¥77m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2023-03-31 | −¥77m |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | ¥43.9bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥1.1bn |
| Animal Health Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥4m |
| Animal Health Businessreportable segment | employees | at 2023-03-31 | 36 pure |
| Animal Health Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥6.7bn |
| Animal Health Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥6.7bn |
| Animal Health Businessreportable segment | segment assets | at 2023-03-31 | ¥3.0bn |
| Animal Health Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥409m |
| Pharmaceutical Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥2.5bn |
| Pharmaceutical Businessreportable segment | employees | at 2023-03-31 | 610 pure |
| Pharmaceutical Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥53.6bn |
| Pharmaceutical Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥53.6bn |
| Pharmaceutical Businessreportable segment | segment assets | at 2023-03-31 | ¥40.1bn |
| Pharmaceutical Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥5.8bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2022-04-01 → 2023-03-31 | ¥2.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2023-03-31 | ¥60.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2023-03-31 | ¥60.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥77m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2023-03-31 | ¥43.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2023-03-31 | ¥6.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-04-01 → 2022-03-31 | ¥259m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-04-01 → 2022-03-31 | ¥185m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥73m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2022-03-31 | ¥90m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-04-01 → 2022-03-31 | −¥16m |
| Reconciling Itemsreconciling | depreciation | 2021-04-01 → 2022-03-31 | ¥136m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2022-03-31 | −¥73m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2022-03-31 | −¥73m |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | ¥37.3bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | −¥653m |
| Animal Health Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥4m |
| Animal Health Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥5.6bn |
| Animal Health Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥5.6bn |
| Animal Health Businessreportable segment | segment assets | at 2022-03-31 | ¥3.0bn |
| Animal Health Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥376m |
| Pharmaceutical Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥2.5bn |
| Pharmaceutical Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥50.8bn |
| Pharmaceutical Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥50.8bn |
| Pharmaceutical Businessreportable segment | segment assets | at 2022-03-31 | ¥42.9bn |
| Pharmaceutical Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥5.1bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2021-04-01 → 2022-03-31 | ¥2.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2022-03-31 | ¥56.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2022-03-31 | ¥56.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥73m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2022-03-31 | ¥46.0bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2022-03-31 | ¥5.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,440
| Item | Context | Value | Unit |
|---|---|---|---|
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row18Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row19Member | Original text (Japanese)有機合成薬品工業㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row19Member | Original text (Japanese)医薬品事業における取引先であり、同社との中長期的な取引関係を維持するため | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row19Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row20Member | Original text (Japanese)㈱バイタルケーエスケー・ホールディングス | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row20Member | Original text (Japanese)医薬品事業等における特約店であり、中長期的な取引関係の維持と強化を図るため | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row20Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row21Member | Original text (Japanese)高砂熱学工業㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row21Member | Original text (Japanese)設備投資等にかかる取引先であり、同社との中長期的な取引関係を維持するため | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row21Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row22Member | Original text (Japanese)㈱スズケン | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row22Member | Original text (Japanese)医薬品事業等における特約店であり、中長期的な取引関係の維持と強化を図るため | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row22Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row23Member | Original text (Japanese)㈱ほくやく・竹山ホールディングス | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row23Member | Original text (Japanese)医薬品事業等における特約店であり、中長期的な取引関係の維持と強化を図るため | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row23Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row24Member | Original text (Japanese)山九㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row24Member | Original text (Japanese)事業経営の観点から中長期的な関係維持と事業拡大図るため | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row24Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row25Member | Original text (Japanese)ダイト㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row25Member | Original text (Japanese)医薬品事業における取引先であり、同社との中長期的な取引関係を維持するため | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row25Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row26Member | Original text (Japanese)ＭＳ＆ＡＤインシュアランスグループホールディングス㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row26Member | Original text (Japanese)取引保険会社を傘下に持つ持株会社であり、同社グループ企業との中長期的な取引関係を維持するため | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row26Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row27Member | Original text (Japanese)大成建設㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row27Member | Original text (Japanese)事業経営の観点から中長期的な関係維持と事業拡大を図るため | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row27Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row28Member | Original text (Japanese)㈱シーボン | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row28Member | Original text (Japanese)その他の事業において取引があり、中長期的な関係の維持と強化を図るため | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row28Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row29Member | Original text (Japanese)そーせいグループ㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row29Member | Original text (Japanese)事業経営の観点から中長期的な関係維持と事業拡大を図るため保有しておりましたが、当事業年度に売却しております。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row29Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row30Member | Original text (Japanese)三井住友トラスト・ホールディングス㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row30Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row30Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row31Member | Original text (Japanese)サワイグループホールディングス㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row31Member | Original text (Japanese)事業経営の観点から中長期的な関係維持と事業拡大を図るため保有しておりましたが、当事業年度に売却しております。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row31Member | Original text (Japanese)無 | |
| Name of securities details of deemed holdings of equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row1Member | Original text (Japanese)㈱三菱ＵＦＪフィナンシャル・グループ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of deemed holdings of shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row1Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of deemed holdings of shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row1Member | Original text (Japanese)有 | |
| Name of securities details of deemed holdings of equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row2Member | Original text (Japanese)㈱三井住友フィナンシャルグループ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of deemed holdings of shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row2Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of deemed holdings of shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row2Member | Original text (Japanese)有 | |
| Name of securities details of deemed holdings of equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row3Member | Original text (Japanese)㈱みずほフィナンシャルグループ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of deemed holdings of shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row3Member | Original text (Japanese)財務面において同社グループ企業との長期的な関係を維持するため（議決権行使に関する指示権限を有する） | |
| Whether issuer of aforementioned shares holds reporting companys shares details of deemed holdings of shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row3Member | Original text (Japanese)無 | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYearDuration | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 22 of 22 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |